Scarica l'app Stockscreener
29.14
6.66%
1.82
Dopo l'orario di chiusura:
29.14
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Trading (AGIO) With Integrated Risk Controls - news.stocktradersdaily.com
Agios to Present at the 2025 RBC Capital Markets Global Healthca - GuruFocus
Agios Pharmaceuticals' (NASDAQ:AGIO) Attractive Earnings Are Not All Good News For Shareholders - Yahoo Finance
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 | AGIO Stock News - GuruFocus
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 - The Manila Times
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Encourages AGIO Shareholders to Contact the Firm - ACCESS Newswire
Alpha Thalassemia Market Trends, Growth Forecast & Treatment - openPR.com
Agios pharmaceuticals outlines key catalysts for PYRUKYND pipeline in 2025 - MSN
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Pharmaceuticals (AGIO) Price Target Adjusted by Scotiabank - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Scotiabank cuts Agios Pharma stock target to $71, keeps outperform rating - Investing.com UK
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 | AGIO Stock News - GuruFocus
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 - The Manila Times
Agios to Reveal Latest Rare Disease Therapeutic Advances at Major BofA Healthcare Conference - Stock Titan
Agios Pharmaceuticals Inc Reports Q1 2025 EPS of -$1.55, Beating - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlight - GuruFocus
Agios Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AGIO) - Seeking Alpha
Agios (AGIO) Reports Lower Q1 Revenue as sNDA for Thalassemia Pr - GuruFocus
Agios Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Agios Pharmaceuticals Shares Down After Q1 Net Loss Widens, Revenue Misses Estimates - marketscreener.com
AGIOS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Earnings call transcript: Agios Pharm beats EPS expectations in Q1 2025 - Investing.com
Agios Q1 2025 slides: PYRUKYND sales dip QoQ, pipeline advances toward key catalysts - Investing.com
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Agios Pharmaceuticals: Q1 Earnings Snapshot - MySA
Agios Reports First Quarter 2025 Financial Results and Recent Bu - GuruFocus
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Earnings Flash (AGIO) Agios Pharmaceuticals Posts Q1 Loss of $-1.55, vs. FactSet Est of $-1.81 Loss - marketscreener.com
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio - ADVFN
An Overview of Agios Pharmaceuticals's Earnings - Nasdaq
Long Term Trading Analysis for (AGIO) - news.stocktradersdaily.com
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for - MSN
BofA Adjusts Price Target on Agios Pharmaceuticals to $52 From $54, Keeps Buy Rating - marketscreener.com
Agios Pharmaceuticals (AGIO) Price Target Lowered by BofA but Buy Rating Maintained | AGIO Stock News - GuruFocus
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 | AGIO Stock News - GuruFocus
Agios Pharmaceuticals to Host Conference Call for Q1 2025 Financial Results on May 1, 2025 - Nasdaq
Rare Disease Biotech Agios Sets Q1 2025 Earnings Call: Key Updates Expected May 1 - Stock Titan
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 - The Manila Times
Anemia Market Set to Witness Significant Growth by 2032, Driven by Rising Awareness and Novel Oral Alternatives | DelveInsight - Barchart.com
Trexquant Investment LP Increases Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock By Investing.com - Investing.com India
Agios Pharmaceuticals director Jacqualyn Fouse sells $194,172 in stock - Investing.com Australia
Agios Pharmaceuticals Director Sells Shares to Cover Tax Obligations - TradingView
Agios stock touches 52-week low at $24.33 amid market challenges - Investing.com Australia
Agios stock touches 52-week low at $24.33 amid market challenges By Investing.com - Investing.com South Africa
RBC Capital Sticks to Its Buy Rating for Agios Pharma (AGIO) - The Globe and Mail
Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says - MarketScreener
4.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):